HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotech Amyris: ‘We Have Built The Fastest-Growing Consumer Business In Health, Beauty And Wellness’

Executive Summary

Emeryville, CA-based Amyris launches the Stripes menopause care line with actress Naomi Watts, as well as Gen Z-targeted EcoFabulous skin care and cosmetics, acquired last year. The biotech projects its burgeoning Consumer business will grow more than 150% in 2022.

You may also be interested in...

Biotech Amyris Targeting 150% Consumer Biz Growth In 2022, Up To 40% In Ingredients Arm

The Emeryville, CA-based synthetic biotech firm projects big growth in 2022 as customers seek out “the purest, cleanest and most sustainably sourced natural ingredients in the world.” Amyris’ business is split between Technology Access and Consumer, the latter set to more than double this year.

Amyris Announces Gen Z-Focused EcoFabulous As Latest Acquisition In $12m Portfolio Enrichment

Brands under development and recent acquisitions including EcoFabulous, Costa Brazil and Terasana will account for around 20% of overall 2021 revenue in Amyris’ Consumer business, according to the firm, which aspires to be the “L’Oreal of clean beauty.”

Renewable Ingredient Firm Signs Givaudan, Boasts $10 Mil. "Pipeline Of Interest"

Renewable ingredients supplier Amyris is positioning itself as a go-to player in the sustainable cosmetics arena, projecting nearly $10 million in potential sales of cosmetic emollient squalane and announcing a new deal with Swiss fragrance house Givaudan.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts